Hybrid Coronary Revascularization (HCR) combines minimally invasive coronary artery bypass grafting (CABG), typically using a left internal mammary artery (LIMA) graft to the left anterior descending artery (LAD), with percutaneous coronary intervention (PCI) using drug-eluting stents (DES) for non-LAD lesions. This approach aims to merge the benefits of durable surgical grafts with reduced procedural morbidity and faster recovery associated with PCI. This study evaluates clinical outcomes, mortality, long-term patency, and repeat revascularization rates in 1,070 patients who underwent HCR across three tertiary centers over six years. HCR demonstrated lower repeat revascularization (11.4%) compared to conventional CABG alone (15.7%) and multi-vessel PCI (22.3%). Hospital stay duration and intensive care utilization were significantly reduced. The findings support HCR as a viable alternative for multi-vessel coronary artery disease, particularly in high-risk patients.